Mounjaro, manufactured by Lilly ... head-to-head battles began in 2012 with Lilly’s once-weekly injectable Trulicity taking on Novo Nordisk’s once-daily injectable Victoza — and the gamble ...
The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback